On February 11, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, reported that Abizer Gaslightwala, CEO of Akari Therapeutics, participated in a Virtual Investor "What This Means" interview focused on the Company’s expanding ADC pipeline and intellectual property strategy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the segment, Mr. Gaslightwala discussed Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors. The discussion highlighted how this milestone underscores the scalability of Akari’s PH1-powered ADC platform and its ability to generate multiple differentiated therapeutic programs.

Mr. Gaslightwala also addressed Akari’s differentiated approach to CEACAM5 through its novel antibody construct combined with the PH1 spliceosome-modulating payload, as well as the Company’s execution priorities as its lead program, AKTX-101, advances toward IND and CTA submission and first-in-human studies. In addition, the segment explored the strategic importance of Akari’s growing patent estate in supporting long-term value creation and potential partnering opportunities.

The Virtual Investor "What This Means" segment featuring Akari Therapeutics is now available here.

(Press release, Akari Therapeutics, FEB 11, 2026, View Source [SID1234662591])